Clinical Trial News and Research RSS Feed - Clinical Trial News and Research

Pharma Two B reports positive results from P2B001 Phase IIb study for treatment of early stage PD

Pharma Two B reports positive results from P2B001 Phase IIb study for treatment of early stage PD

Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs, announced today the successful results of the company's Phase IIb pivotal study of P2B001 for the treatment of early stage Parkinson's Disease (PD). [More]
BioLight receives CE Mark approval for CellDetect bladder cancer test

BioLight receives CE Mark approval for CellDetect bladder cancer test

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that its CellDetect non-invasive test for detecting bladder cancer in urine has obtained CE Marking, enabling the product to be marketed and sold in Europe and other territories. [More]
First participant enrolled in RepliCel's RCT-01 Phase 1/2 clinical trial for treatment of chronic tendinosis

First participant enrolled in RepliCel's RCT-01 Phase 1/2 clinical trial for treatment of chronic tendinosis

RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that the first participant in its Phase 1/2 clinical trial of RCT-01, being tested for the treatment of chronic unilateral Achilles tendinosis, has been enrolled and their tissue biopsy sent for processing prior to intra-tendon ultrasound-guided injections. [More]
BiondVax’s universal influenza vaccine meets safety and immunogenicity endpoints

BiondVax’s universal influenza vaccine meets safety and immunogenicity endpoints

BiondVax Pharmaceuticals Ltd. today announced positive preliminary results from its BVX-006 Phase II clinical trial of M-001, BiondVax's candidate for a universal influenza vaccine. [More]
Marken to deliver direct to patient shipment of drugs in Korea during MERS outbreak

Marken to deliver direct to patient shipment of drugs in Korea during MERS outbreak

Marken, the leading clinical trial logistics organization providing solutions and services to the life sciences industry, has been granted permission by the government to deliver the first direct to patient shipment of clinical drug product in Korea. [More]
New technique that mines Twitter data can help identify potentially dangerous drug interactions

New technique that mines Twitter data can help identify potentially dangerous drug interactions

A team of scientists has invented a new technique for discovering potentially dangerous drug interactions and unknown side-effects — before they show up in medical databases, like PubMed, or even before doctors and researchers have heard of them at all. [More]
Asterias Biotherapeutics added to Russell indexes

Asterias Biotherapeutics added to Russell indexes

Asterias Biotherapeutics, Inc., a biotechnology company focused on the emerging field of regenerative medicine, today announced that it has been added to the Russell 2000, Russell 3000, Russell Global and Russell Microcap indexes following Russell Investments' ("Russell") reconstitution of its comprehensive set of U.S. and global equity indexes after the close of the U.S. markets on June 26, 2015. [More]
BioClinica expands presence in Europe

BioClinica expands presence in Europe

BioClinica, Inc., the world's leading specialty clinical trial service provider, announced today the opening of new and expanded offices in London and Munich to better serve its growing client base in Europe. [More]
Government of the Republic of Equatorial Guinea to sponsor development of Sanaria PfSPZ Vaccine for malaria

Government of the Republic of Equatorial Guinea to sponsor development of Sanaria PfSPZ Vaccine for malaria

The Government of the Republic of Equatorial Guinea announced an agreement with industry partners, Marathon Oil Corporation, Noble Energy Inc. and AMPCO, to sponsor the clinical development of Sanaria PfSPZ Vaccine against malaria, including a series of clinical trials from 2015 until 2018. [More]
Study may predict which glioblastoma patients may respond well to dasatinib drug treatment

Study may predict which glioblastoma patients may respond well to dasatinib drug treatment

Clinicians testing the drug dasatinib, approved for several blood cancers, had hoped it would slow the aggressive growth of the deadly brain cancer glioblastoma; however, clinical trials to date have not found any benefit. Researchers at Mayo Clinic, who conducted one of those clinical trials, believe they know why dasatinib failed — and what to do about it. [More]
SLU's Center for Vaccine Development receives $2.9 million to study new vaccine to combat TB

SLU's Center for Vaccine Development receives $2.9 million to study new vaccine to combat TB

Saint Louis University's Center for Vaccine Development has received a $2.9 million award from the Bill & Melinda Gates Foundation to study a new tuberculosis vaccine. [More]
Axovant Sciences accepts two presentations at Alzheimer's Association International Conference 2015

Axovant Sciences accepts two presentations at Alzheimer's Association International Conference 2015

Axovant Sciences Ltd., a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced the acceptance of two presentations at the Alzheimer's Association International Conference 2015 (AAIC) being held in Washington, D.C. from July 18-23, 2015. [More]

FDA accepts TxCell’s IND application for Ovasave for treatment of refractory Crohn’s disease

TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that the United States Food and Drug Administration has accepted TxCell’s Investigational New Drug application for the company’s lead product, Ovasave(R), currently in a phase 2b clinical trial for the treatment of patients with refractory Crohn’s disease. [More]
Synthetic Biologics announces initiation of SYN-010 Phase 2 clinical trial for treatment of IBS-C

Synthetic Biologics announces initiation of SYN-010 Phase 2 clinical trial for treatment of IBS-C

Synthetic Biologics, Inc., a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, reported the initiation of a Phase 2 clinical trial of its proprietary SYN-010 for the treatment of irritable bowel syndrome with constipation (IBS-C). [More]
Spinifex Pharmaceuticals enters into agreement to be acquired by Novartis

Spinifex Pharmaceuticals enters into agreement to be acquired by Novartis

Spinifex Pharmaceuticals, Inc., a company focused on the development of new drugs for the treatment of chronic pain, today announces that it has agreed to the sale of Spinifex to Novartis International AG, for an upfront cash consideration of US$200 million plus undisclosed clinical development and regulatory milestone payments. [More]
Two physician-scientists in search for better Alzheimer's disease treatment

Two physician-scientists in search for better Alzheimer's disease treatment

Two of the nation's leading physician-scientists in the search to better understand and treat Alzheimer's disease - William Mobley, MD, PhD, and Michael Rafii, MD, PhD - have been named interim co-directors of the Alzheimer's Disease Cooperative Study (ADCS), a major initiative formed in 1991 as a cooperative agreement between the National Institute on Aging (NIA) and the University of California, San Diego. [More]
Neuralstem's HK532-IGF-1 neural stem cells therapy for Alzheimer's disease presented at ISSCR Annual Meeting

Neuralstem's HK532-IGF-1 neural stem cells therapy for Alzheimer's disease presented at ISSCR Annual Meeting

Neuralstem, Inc., a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced that the poster "Human Neural Stem Cells Expressing IGF-1: A Novel Cellular Therapy for Alzheimer's Disease" was presented yesterday at the International Society for Stem Cell Research (ISSCR) Annual Meeting in Stockholm, Sweden. [More]

IDC Marketscape recognizes TCS as Leader in Worldwide Life Sciences R&D Risk-Based Monitoring

Tata Consultancy Services, a leading global IT services, consulting and business solutions organization, announced that it has been designated as a Leader in Worldwide Life Sciences R&D Risk-Based Monitoring by global market intelligence firm, IDC, in the "IDC MarketScape: Worldwide Life Science R&D Risk-Based Monitoring 2015 Vendor Assessment," (doc #HI255628, April 2015) report. [More]
ASTRO appreciates Supreme Court's decision to uphold consumer tax credits under the ACA

ASTRO appreciates Supreme Court's decision to uphold consumer tax credits under the ACA

The American Society for Radiation Oncology appreciates yesterday's ruling by the United States Supreme Court affirming the Affordable Care Act in its decision on King v. Burwell. [More]
CTCA at Western begins Phase Ib/II trial of new immunotherapy treatment for cancer patients

CTCA at Western begins Phase Ib/II trial of new immunotherapy treatment for cancer patients

Cancer Treatment Centers of America at Western Regional Medical Center in Goodyear, Arizona, has begun a new Phase Ib/II clinical trial using a new immunotherapy treatment for patients with advanced kidney, non-small cell lung cancer, pancreatic cancer and colorectal carcinoma. [More]
Advertisement
Advertisement